eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

5/2022
vol. 14
 
Share:
Share:
Review paper

Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites

Mehdi Kazemi
1
,
Sarah Nadarajan
1
,
Mitchell Kamrava
2

  1. Department of Internal Medicine, UHS Southern California Medical Education Consortium, United States
  2. Department of Radiation Oncology, Cedars Sinai Medical Center, United States
J Contemp Brachytherapy 2022; 14, 5: 481–494
Online publish date: 2022/11/25
Article file
- Single-fraction.pdf  [0.26 MB]
Get citation
 
 

Purpose

Brachytherapy is a versatile treatment that delivers highly concentrated doses of radiation to tumor targets while limiting dose to surrounding organs at risk. It can conveniently be given in a single-session using low-dose-rate brachytherapy (LDR-BT), whereas high-dose-rate brachytherapy (HDR-BT) is more traditionally applied over multiple treatment fractions. HDR-BT does have planning advantages over LDR-BT in that the dose that will be delivered can be determined prior to its’ delivery, and the patient does not need to go home with any radioactive seeds. Whether HDR-BT can be delivered as a single-fraction treatment with similar oncologic outcomes and acute/late toxicities as multi-fractionated regimens, is not well-known.

The purpose of this study was to review the literature on single-fraction HDR brachytherapy for the treatment of all disease sites, to evaluate the extent of published literature on this topic.

Material and methods

A scoping review was performed using the PubMed database, and according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The PubMed database was queried with the following search terms from 1994-2021: ‘brachytherapy’, which generated 26,899 results, ‘high-dose-rate’, which generated 5,356 results, and ‘single-fraction’, which generated 56,908 results. A combined search of ‘brachytherapy AND high-dose-rate AND single-fraction’, yielded 454 results.

The results were reviewed by three authors for inclusion/exclusion (MK, SN, and MK). From the initial 454 records for review, 357 were excluded as they were irrelevant, they were dosimetry studies, or multi-fraction treatments. As a result, 97 reports were sought for retrieval, of which one was not retrieved as the full article was not available on PubMed. From the 96 reports that were assessed for eligibility, 43 papers were excluded for the following reasons: 9 had the same cohort, 11 with follow-up less than 1 year, 4 with sample size less than 10 patients, 5 reports with combination of both follow-up less than 1 year and sample size less than 10 patients, 4 case reports, 6 review articles, and 4 studies that were not applicable. Therefore, 53 studies were included in the final scoping review (Figure 1).

Fig. 1

PRISMA diagram. Identification of studies via databases and registers

/f/fulltexts/JCB/48268/JCB-14-48268-g001_min.jpg

Prostate

Clinical outcomes

Seventeen studies (14 definitive, 1 focal definitive, and 2 focal salvage) with 1,474 patients reported on single-fraction treatment between 2016-2021 (Table 1). Six studies were from the UK, 3 from the USA, 3 from Spain, 3 from Canada, 1 from the Netherlands, and 1 from Italy. Single-fraction dose delivered ranged from 19 to 21 Gy. Eight studies treated patients with androgen deprivation therapy treatment over a range between 3 and 36 months. In the definitive therapy series, median follow-up ranged from 20 to 72 months, while in the salvage series it ranged from 25 to 26 months [1-17].

Table 1

Single-fraction prostate high-dose-rate brachytherapy (HDR-BT) studies

Author(s),
year
Study
type
Def/salvageNo. of patientsPatient risk groupADTDose (Gy)Median follow-up (months)Biochemical controlFreedom from local failureToxicity
(CTCAE)
Armstrong et al., 20211ProsDefGroup 1: 25
Group 2: 25
Group 1:
L: 0%
I: 44%
H: 56%
Group 2:
L: 4%
I: 40%
H: 56%
6 m int.-risk
18-36 m high-risk
21 to DIL with SIB
Group 1: V19 Gy < 75%
Group 2: V19 Gy < 50%
70.6
Group 1: 75
Group 2: 57
Group 1: 5 y. – 88%
Group 2: 5 y. – 76%
Group 1: 5 y. – 96%
Group 2: 5 y. – 84%
Acute:
12% G2 GU
0% ≥ G3 GU
Late:
0% ≥ G2 GI
3 pts. G3 urethral strictures
Tsang et al., 2021ProsDef78L: 4%
I: 96%
6 m if T2c and either PSA > 10 or GS 71948.55 y. – 69%N.R.5 y. ≥ G2 GU 30%
5 y. ≥ G2 GI 0%
Tharmalingam et al., 20202ProsDef441L: 10%
I: 65%
H: 25%
38% median: 6 m19263 y. – 88%
(L: 100%, I: 86%, H: 75%)
15 local with 11 isolated local failuresAcute G2 GU/GI: 12%/3%
2 pts. late G3 GU
2 pts. late G3 GI
Hoskin et al., 2017ProsDef49I: 57%
H: 43%
74% (median duration 7 m)19-20494 y. – 94%N.R.Late 4 y. G3 GU/GI G3 2%/0%
Soatti et al., 2020RetroDef8719-20726 y. – 65%
(L: 90%, I: 90%, H: 76%)
Barnes et al., 2019RetroDef28L: 50%
I: 50%
1 pt. (short-term)19-20
(2 pts. 20)
283 y. – 81% (in 19 Gy group)
(L: 86%, I: 79%)
3 y. – 86%18% late G2 GU
No late ≥ G3 GI or GU
Xu et al., 2019RetroDef124L: 21%
I: 79%
None19264 y. – 78%
(I: 86%)
12 pts. with recurrence
10 with imaging had local recurrence
8 had biopsy-proved local recurrence
Late GU1/2: 22%/60%
No acute/late ≥ G3 GU/GI
Siddiqui et al., 20193ProsDef68L: 59%
I: 41%
None19475 y. – 77%
(L: 79%, I: 75%)
5 y. – 81%Late ≥ G2 GU: 15%
Late ≥ G2 GI: 6%
Peters et al., 2019,
Maenhout et al., 2018
ProsDef30L: 13%
I: 87%
NoneFocal: 19484 y. – 70%Local recurrence in 9/10 pts. with biochemical failure; 7/9 out-of-fieldNo late ≥ G2 GI
1 late G2 GU
Gomez-Iturriaga et al., 2017ProsDef43L: 44%
I: 56%
None1920N.R.N.R.2 y. – GI ≥ G1: 0%
2 y. GU G1/2/3: 14%/2%/0%
Reynaud et al., 2021ProsDef16N.R. for this armNone194581%N.R.0 G2 GU
1 G2 GI
Prada et al., 2016Def60L: 73%
I: 27%
3 m: 33%19726 y. – 66%
(L: 82%, I: 79%)
88% free of local recurrenceLate G3 GI/GU: 0%/0%
Prada et al., 2018Def60L: 37%
I: 57%
3 m: 43%20.5516 y. – 82%92%Late GI: none
0 late ≥ G2 GU
Slevin et al., 2020RetroSalvage43Prim tumor risk category
L: 30%
I: 40%
H: 30%
74%
44%
6 m
21%: 2-3 y.
Focal: 19263 y. – 42%Local recurrence in 16%Late G3 GU/GI: 2%/0%
Willigenburg et al., 2021ProsSalvage150Prim tumor risk category
L: 18%
I: 37%
H: 39%
Focal: 1925Model 1 2 y.:
L: 84%
I: 70%
H: 31%
Model 2 2 y.:
L: 100%
I: 71%
H: 5%
N.R.N.R.
Alayed et al., 20214ProsDefTrial 1: 87
Trial 2: 60
Trial 1:
L: 23%
I: 75%
Trial 2:
L: 8%
I: 90%
Trial 1: None
Trial 2: None
19 whole gland, 19 whole gland/23 focal boostTrial 1: 62
Trial 2: 50
Trial 1: 5 y. – 67%
Trial 2: 5 y. – 69%
Trial 1 and 2 combined: (L: 91%, I: 76%)
78% of failures localTrial 1:
Late G3 GU/GI: 2%/0%
Trial 2:
Late G3 GU/GI: 0%/0%

* Study included 4, 2, and 1 fraction HDR-BT monotherapy, but did not stratify the outcomes separately, except for PSA control for the 19-20 Gy group

Of the 14 studies that treated patients with definitive intent, prostate specific antigen (PSA) control rates ranged from 65 to 94% (Figure 2). Seven studies stratified PSA control based on risk groups. PSA control rates for low-risk patients ranged from 79% to 100%, for intermediate-risk patients ranged from 75% to 86%, and for high-risk patients ranged from 75% to 76% (Figure 3).

Fig. 2

Biochemical control rates in single-fraction prostate cancer definitive treatment studies

/f/fulltexts/JCB/48268/JCB-14-48268-g002_min.jpg
Fig. 3

Risk stratified biochemical control rates in singlefraction prostate cancer definitive treatment studies

/f/fulltexts/JCB/48268/JCB-14-48268-g003_min.jpg

The most significant study reported was a randomized controlled trial of single-fraction 19 Gy vs. two fractions of 13.5 Gy [18]. This study included 170 patients with either low- or intermediate-risk, with no prior androgen deprivation therapy. Median follow-up was 60 months. The study resulted in a significantly higher rate of PSA biochemical failure in the single-fraction arm. G3 genitourinary (GU) toxicity was only seen in 3% in the single-fraction arm and no reported cases in the two-fraction arm; however, this was statistically insignificant between both groups.

When reviewing patterns of failures after single-fraction treatment, high rates of local failures were reported in a dominant intra-prostatic lesion. Studies that reported on local failure rates reported that this occurred in 4-78% of cases. Attempts to reduce failures in the dominant intra-prostatic lesion by increasing the single-fraction dose have not been successful to date. Prada et al. increased the whole gland single-fraction dose to 20.5 Gy [9], and Armstrong et al. performed a focal boost of 21 Gy to the dominant intra-prostatic lesion [2], but there were still higher than expected failures compared with a multi-fraction regimen. For patients treated with salvage treatment, two studies reported on outcomes with 2-year PSA control rates ranging from 42% to 59%. These results, similar to the definitive setting, demonstrated less than ideal outcomes with single-fraction treatment [12, 16].

Toxicities

Acute G1-G2 GU toxicities were reported in 0-12%, while acute G1-G2 gastrointestinal (GI) toxicities were reported in 0-3% of patients. Acute G3 or higher GU or GI toxicities were reported in 0%. Late G1-G2 GU toxicities were reported in 0-60%, while late G1-G2 GI toxicities were reported in 0-6%. Late G3 or higher GU or GI toxicities were reported in 0-6%. Types of late G3 toxicities reported were urethral strictures [2], rectal fistulae [14], chronic diarrhea [11] that was medically managed, and obstruction of the urinary tract that necessitated TURP [1].

Breast

Seven studies (all definitive after lumpectomy) with 268 patients were reporting on receiving single-fraction treatment between 2008-2021 (Table 2). Five studies were from France, 1 from Spain, and 1 from the USA. Single-fraction high-dose brachytherapy dose delivered ranged between 16 and 21 Gy. Median ages of patients treated ranged from 64 to 77 years, and included patients with early-stage breast cancer [18-24].

Table 2

Single-fraction breast high-dose-rate brachytherapy (HDR-BT) studies

Study (year)No. of patientsMedian age (years)Median lesion size (cm)Single- fraction dose (Gy)Median follow-up (months)LR (months)DFS (months)Median OS
(months)
Acute toxicitiesChronic toxicitiesCosmesis (excellent or good)
Sacchini (2008)5276< 2201
182
31.40%4% re-operation for poor wound healingAt 12 m, 9% seroma, 3% wound infection, or necrosis, 3% painBetter cosmesis scores in patients treated with 18 Gy than 20 Gy
Latorre (2018)2063.5< 318240% (24)95% (24)100% (24)No G3 toxicities or higher observedNo differences in cosmetic results pre or post therapy
Kinj (2018)4877.71.216400% (40)100% (36)93.1% (36)2 patients had G3 breast hematomas
1 patient had G3 breast abscess
No G3 toxicities or higher observed76%
Kinj (2019)4877.71.216640% (64)100% (60)87.3% (60)Previously reported in Kinj 2018No G3 toxicities or higher observedExcellent: 76.4%
Good: 25.6%
Hannoun-Lévi (2020)2676.61.0416630% (60)100% (60)88.5% (60)G3 events: 4.5%No G3 toxicities or higher observedExcellent: 80.8%
Good: 19.2%
Hannoun-Lévi (2021)4875116720% (72)82.2% (72)82.2% (72)G3 events: 4.5%3No G3 toxicities or higher observed98%
Boulahssass (2021)2677< 2166388%

[i] LR – local recurrence; DFS – disease-free survival; OS – overall survival; 1the first 18 patients were treated with a single-fraction dose of 20 Gy; 2given high rates of acute toxicities with 20 Gy, the remaining 34 were treated with a single-fraction dose of 18 Gy; 3the paper did not distinguish between the G3 events in the hyper-fractionated and single-fraction group

Median reported follow-up ranged from 24 to 72 months. At 6 years, freedom from local recurrence (LR) was 100%, disease-free survival (DFS) ranged from 82% to 100%, and median overall survival (OS) ranged from 82% to 100%.

Toxicities

Single-fraction treatment appeared to be well-tolerated in acute and late term settings. Amongst the doses used, Sacchini’s paper initially assessed a single-fraction dose of 20 Gy. However, due to increased acute toxicity rates, the dose was lowered to 18 Gy [24]. This is also a unique series that used an HDR applicator intra-operatively, and the dose distribution with this approach was very different from that of the other papers, which used an interstitial technique. For papers that used doses in the 16-18 Gy range, serious acute toxicities were seen in < 5% of patients. No grade 3 or higher late toxicities have been reported to date. Excellent to good cosmesis outcomes were reported in 76-98% of patients. These early to mid-term results of single-fraction brachytherapy appear promising for this highly selected group of favorable patients. Longer term data is needed to confirm the favorable oncologic and cosmetic results.

Liver

Eighteen studies (7 primary, 11 metastasis) with 618 patients have been reported on receiving single-fraction treatment between 2004-2021 (Table 3). Seventeen studies were from Germany, and one was from Poland [25-42]. Single-fraction high-dose brachytherapy dose delivered ranged from 8 to 25 Gy. Median follow-up range for series that treated a primary liver cancer was 12-23 months, and median follow-up range for series that treated liver metastasis ranged from 11 to 28 months. Local control range for primary disease ranged from 37% to 93%, and local control range for metastasis ranged from 40% to 94% (Figure 4). Furthermore, Denecke et al. focused on comparing single-fraction brachytherapy as a bridge to liver transplant compared with the standard modality of transarterial chemoembolization (TACE). This study showed that for patients who are not candidates for TACE, single-fraction treatment may be an acceptable alternative modality [28]. There are large variations in the local control rates reported. Much of this seems to be related to the dose given as well as the size of the tumor treated. Ricke et al. showed in a dose escalation trial, for example, improved local control rates when increasing the dosage from 15 Gy to 25 Gy in a single-fraction [33].

Table 3

Single-fraction liver high-dose-rate (HDR) studies

EntityStudy (year)No. of patientsMedian age (years)Median lesion size (cm)Single- fraction dose (Gy)Median follow-up
(months)
LTC (months)PFS
(months)
Median OS (months)Toxicities
Primary hepatic malignanciesCollettini (2012)356817.115212.88.75
Distant tumor progression: 30%
15.4No major complications
5 patients lost to follow-up
Colletini (2015)9870116.5223.121.115.2
Distant tumor progression: 68.4%
29.2
80.0% (12)
62.0% (24)
46.0% (36)
Mortality 43.9%
12 patients lost to follow-up
Denecke (2015)125911218.9 (15-25)210% (12)4
10% (36)4
1 patient had arterial bleeding post-removal of brachytherapy catheters requiring embolization
Schnapauff (2015)19203332.120
50Mortality: 42%
3 patients lost to follow-up
1 patient had post-interventional hepatic hemorrhage that spontaneously tamponated
Walter (2021)38672.9215
Tselis (2013)22648438 (7-14)12.490% (6)
81% (12)
50% (18)
13.2Mortality: 80%7
No procedure-related deaths
Major complications: 5%8
Schnapauff (2012)156615.252014101314Mortality: 60%
Jonczyk (2018)35661A: 2.04
B: 6.92
A: 20 Gy
B: > 12 Gy
A: (8)
98% (6)
87% (12)
72% (24)
72% (36)
72% (60)
B: (6)
89% (6)
78% (12)
37% (24)
37% (36)
37% (60)
A: (5)
41% (6)
35% (12)
24% (24)
24% (36)
16% (60)
B: (3)
39% (6)
25% (12)
17% (24)
17% (36)
17% (60)
A: (15.5)
94% (6)
68% (12)
61% (24)
46% (36)
36% (60)
B: (10)
75% (6)
63% (12)
36% (24)
16% (36)
12% (60)
Mortality: 57.3%
Secondary hepatic malignanciesRicke (2004)216614.810-201487% (6)
87% (9)
59% (6)
34% (12)
86% (6)6
69% (12)6
1 patient had post-intervention symptomatic liver dysfunction
1 patient had mechanical occlusion of central bile duct requiring endoscopic stenting
Ricke (2004)20661A: 7.4
B: 3.4
17 (12-25)13A: 74% (6)
40% (12)
B:
100% (6)
71% (12)
A: 63% (6)
33% (12)
B:
67% (6)
21% (12)
89% (6)
83% (12)
1 patient had post-interventional intra-abdominal bleeding
1 patient had mechanical occlusion of central bile duct requiring endoscopic stenting
4 patients lost to follow-up. 3:4 patients died
Kieszko (2018)6120
(13-29)
1188.7% (6)
70.7% (12)
78.1% (6)
53.8% (12)
96.7% (6)
79.6% (12)
15 patients succumbed to cancer (24.6%)
No G2 events or greater were observed
Wieners (2009)33644.618 Gy (15-25)2887% (6)
76% (12)
76% (18)
69% (24)
10.55
No progression (6%)
Intra-hepatic (57.5%)
Extra-hepatic (27.2%)
Intra- and extra-hepatic (9%)
25Mortality: 57.6%
1 patient had post-interventional bleeding
1 patient had pneumothorax requiring chest tube
1 patient had biliary abscess requiring percutaneous drainage and antibiotics
Ricke (2010)733.115, 20, and 2515.225.1%6
10.5 (exclude tumor recurrences)
23.4
(first ablation)
46.7
(first diagnosis of liver metastases)
56.2
(first diagnosis of primary tumor)
2 patients had occult blood requiring transfusion
2 patients had symptomatic gastric ulcer
1 patient had pleural effusion treated by pleurodesis
1 patient had anaphylactic reaction to iodide contrast media
Collettini (2014)37662.8519.1 (15-20)16.910.7
88.3% (12)
81.2% (24)
68.4% (36)
Local progression (12.9%)18
87.6% (12)
57.3% (24)
41.6% (36)
43% died from colorectal cancer
Wieners (2015)162.919
(15-20)
13.74.9
No progression (20%)
Intra-hepatic progression (40%)
Extra-hepatic progression (20%)
Intra- and extra-hepatic progression (20%)
8.6
80% (6)
45% (12)
3 post-interventional abscesses (20%)9
Drewes (2019)16622.221
(5-29.1)
86.7% (3.3)3.48.93 patients had G3 liver abscesses post interstitial brachytherapy
Wieners (2011)41554.415-251897% (6)
93.5% (12)
93.5% (18)
8.1
53% (6)
40% (12)
27% (18)
Intra-hepatic progression (58.5%)
Extra-hepatic (7.3%)
Intra- and extra-hepatic progression (19.5%)
97% (6)
79% (12)
60% (18)
30 day mortality (0%)
Symptomatic post-interventional blood loss through puncture site (1.4%)
Schippers (2017)27632.115296.3% (3)No progression (88.9%)
Local progression (11.1%)
30.3No post-interventional mortality
Hepatic abscess (11.1%)10

[i] LTC – local tumor control; PFS – progression-free survival; OS – overall survival; 1mean age; 2mean or minimum; 3median volume (cm3); 4local recurrence rates were better with brachytherapy compared with trans-arterial chemo-embolization, 5unspecified if PFS rates applied to one or all three groups were evaluated, 6unspecified if OS rates were from high-dose-rate (HDR) brachytherapy alone or HDR + laser-induced thermal treatment, 78 of 10 patients with local tumor progression died from poor liver function, 8unspecified if complications occurred in single-fraction or fractionated groups (2 cases of intra-abdominal hemorrhage, and 1 case of Gram-negative septicemia); 9abscesses secondary to ascending biliary infection in patients who underwent Whipple’s or pylorus-preserving resection of pancreatic head in patients with biliodigestive anastomosis; 101 of 3 patients with biliodigestive anastomosis developed hepatic abscess 4.9 months post-ablation

Fig. 4

Local control rates for primary and metastatic liver disease

/f/fulltexts/JCB/48268/JCB-14-48268-g004_min.jpg

Toxicities

G3 toxicity was reported in 3 patients with liver abscesses post-interstitial brachytherapy in a study done by Drewes et al. [29]. Other serious complications were noted, including post-interventional abdominal hemorrhage, pneumothorax, biliary abscess [41], and Gram-negative septicemia [38]; however, only a few cases were reported with such complications (Table 3). Overall single-fraction HDR-BT appeared to be a safe modality given a low number of serious toxicities reported to date.

Other cancers

Eleven published studies met the inclusion criteria in assessing the efficacy of single-fraction high-dose brachytherapy for cancers other than prostate, breast, and liver. The studies were published by groups in the following locations: 4 from the USA, 3 from Germany, 1 from Italy, 1 from the United Kingdom, 1 from China, and 1 from Spain [43-53]. Table 4 summarizes the oncological outcomes and toxicities for these eleven publications. There were 3 studies for gastrointestinal, 2 studies for head and neck, 3 studies for lung, 1 study for gastrointestinal stroma tumor, 1 study for glioma, and 1 study for endometrial carcinoma. Amongst these studies, lung appears to have promising data. Yoon et al. reported on 23 patients treated with 21.5 Gy single-fraction HDR brachytherapy, with local control of 96% at 2 years for centrally located primary and metastatic lung cancer, and no G3 or higher toxicities were reported [52]. Xiang et al. also reported on single-fraction HDR lung brachytherapy in a phase I clinical trial. A single-fraction of 30 Gy brachytherapy to the primary in combination with intensity-modulated radiation therapy (IMRT) to nodal regions while receiving concurrent chemotherapy resulted in 82% local tumor control at 2 years [51]. It is difficult to make any definite conclusions regarding the efficacy of single-fraction brachytherapy for lung or these other less common sites, given the limited data for each type of cancer.

Table 4

Single-fraction other sites high-dose-rate brachytherapy (HDR-BT) studies

EntityStudy (year)No. of patientsMedian age (years)Mean lesion size (cm)Single- fraction dose (Gy)Median follow- up
(months)
LTC (months)PFS
(months)
Median OS
(months, %)
Definitive or salvageToxicities
GIKolotas (2003)3863110-1523.4Local progression: 10.5%
Partial remission: 15.7%
15SalvageMortality: 65.7%
1 patient developed a fistula6
1 patient developed an abscess7
Hoskin (2004)2282101107.2SalvageNo significant acute toxicity
9 deaths due to causes other than progression of malignancy with 3 cases unknown
Omari (2019)1263219.9 (5.4-22)8.3489%6.511.4Salvage1 patient had G3-infected hepatic hematoma8
GISTOmari (2019)10582.415
(6.7-22)
24.697.5% (25)6.837.3DefinitiveMortality: 60%
1 patient had G3 hepatic hemorrhage9
1 patient had G3 pneumothorax10
GliomaFabrini (2009)21601832.38.6
42% (6)
21.7DefinitiveMortality: 71%
1 patient had G5 fatal post-operative hemorrhage (day 1)
1 patient had G3 CSF leak
Head and neckNag (2005)18611103
(7.5-20)
6577% (12)
69% (36)
59% (60)
72% (12)
65% (36)
53% (60)
50
12 (83%)
36
(63%)
60
(42%)
Definitive and salvageNo major intra-operative or acute post- operative complications
3 deaths from post-operative complications
1 death from septicemia due to chemotherapy
6 deaths from unrelated causes
Teckie (2013)575415
(12-20)
1667% (12)5
57% (36)5
Local recurrence PFS:
63% (12)
41% (36)
12
(75%)
36
(43%)
DefinitiveMortality: 70%
G3 late events: 16%
No G4-5 events observed
LungChan (2010)17743218 (14.4-20)2283% (24)76% (24)21 (53%)SalvageMortality: 64.7%
1 patient died from pneumonia
1 patient died from second primary cancer
No treatment-related deaths
Yoon (2021)236621.5 (15-27.5)1996.2% (24)
96.2% (36)
29.7% (24)
65.5% (36)
Complete local response: 18.2%
Partial response: 45.5%
Stable disease: 33.3%
Local progression: 3%
24
(30%)
36
(66%)
DefinitivePneumothorax requiring chest tube placement 10.3%
No G3 events observed
Xiang
(2015)
26684.230 Gy (GTV)11
70 Gy
(PTV)12
2882%
(24)
23 (67%)Salvage3 mild pneumothoraces
Mild lung fibrosis
Endometrial
carcinoma
Zhang (2020)10766795.5SalvageG2-4 vaginal (6.5%)
G1-4 rectal (3.7%)
G1-4 bladder (9.3%)

[i] LTC – local tumor control; PFS – progression-free survival; OS – overall survival; 1mean age; 2mean size; 3mean dose; 4mean follow-up; 5one year PFS was 91% for patients treated with dose > 15 Gy, and 61% for patients treated with a dose < 15 Gy; 6patient was previously treated with a Hartmann procedure and developed a fistula; 7patient previously had ulceration in the perineal region secondary to the tumor and developed an abscess; 8patient was successfully treated with transcutaneous drainage and antibiotics; 9patient required embolization with digital subtraction angiography; 10patient required treatment with a pleural drain; 11gross tumor volume with single-fraction HDR-BT; 12PTV using IMRT

Discussion

There is interest in single-fraction treatment both from a patient and hospital system perspectives. Increasing studies are being conducted using single-fraction external beam treatments [54], including randomized clinical trials. Brachytherapy is uniquely positioned to deliver very high doses of radiation in single treatments with rapid fall-off, and may provide various advantages over external beam approaches. Delivering a single-fraction HDR brachytherapy is technically feasible, but there are unanswered questions regarding the safety and efficacy of delivering very high doses of radiation in a single treatment. Determining whether pursuit of such an effort is worthwhile requires an understanding of the current published literature on this topic.

Our literature search identified 53 papers, which were included in this review. A large number of prostate cancer patients have been treated with single-fraction treatment and mostly in the definitive setting. There has even been a randomized controlled trial on two versus single-fraction HDR-BT demonstrating inferior biochemical control in the single-fraction arm [55]. Multiple studies also demonstrate high rates of locally persistent disease predominantly in the dominant intra-prostatic lesion [56]. Further attempts at single-fraction dose escalation has also not significantly improved outcomes [1]. In addition, in reviewing the biochemical control outcomes by risk group, it does not appear that there is a risk group that has acceptable control with single-fraction treatment. Based on the current literature, it does not appear that single-fraction HDR-BT for definitive prostate cancer treatment is an acceptable standard of care. Any future work in this area should be conducted as part of a clinical trial.

The published work on single-fraction treatment in the salvage setting is limited to just two studies, but the overall trends are similar as that seen in the definitive setting, with worse than expected biochemical control compared with multi-fractionated regimens. It seems likely that single-fraction treatment in the salvage setting will also not be ideal regarding long-term oncologic control. The reasons for these less than promising results is not entirely clear. It likely includes an incomplete understanding of radiation biology and accurate conversions of dose using α/β ratio and linear quadratic modelling as well has cell re-assortment and hypoxia. These limitations should be balanced with the possible lower toxicities seen in the short-term with a single-fraction treatment, which is a more pertinent consideration in the re-irradiation setting. However, longer follow-up is needed with single-fraction regimens in this setting. As in the definitive setting, worse GU toxicities have been reported with single- vs. multi-fraction regimens [4].

Single-fraction breast literature appears promising both in terms of early oncologic control and limited toxicities. It is difficult to know whether the high local control rates confirm that single-fraction treatments are truly effective, or whether the relatively low-risk population would not have recurred even without adjuvant radiation. The experience with single-fraction treatment is also mostly limited to one group in France that has used an interstitial technique. There is an ongoing clinical trial with a balloon-based single-fraction technique, which has not reported oncologic outcomes yet [57], but has reported limited severe toxicities to date. Single-fraction external beam treatments are also being developed both in the pre-operative and post-operative spaces [58]. Continued work in this space is needed to determine the ideal single-fraction dose, and long-term oncologic and toxicity outcomes. It is important for future studies to include prospective collection of quality-of-life data, as these would be necessary to understand the place of brachytherapy compared with alternative external beam methods for delivering single-fraction doses.

Single-fraction liver treatments have been published in retrospective, single-arm prospective, and even in randomized controlled trials [59]. Liver single-fraction literature is unique in that dose escalation trials have been performed to find the ideal dose, as previously mentioned in a study by Ricke et al. [33]. Significant work has also been done to determine organ at risk dose constraints, and understanding of the limitations of treating perihilar disease. Local control rates for appropriately sized lesions treated with appropriate single-fraction doses demonstrate local control ranges comparable to stereotactic body radiation therapy or other ablative techniques. Toxicities also seem limited. According to the 2018 ESMO guidelines for hepatocellular cancer, single-fraction liver brachytherapy is now included as a treatment option. These encouraging results in the liver are despite the fact that many patients were heavily pre-treated, and had failed other prior local therapy regimens.

Additional single-fraction studies have been done outside of the prostate, breast, and liver, but are very limited. There is some promising data in the lung, but overall conclusions are limited given the small numbers of patients who have been treated to date.

Our study has some limitations. PubMed was the only queried database, and if we had conducted a systematic review and included additional databases, we may have found more studies. Also, not all studies provided the same categories of data, such as prostate risk groups, which made it more challenging to evaluate certain patients’ sub-groups.

Conclusions

The medium-sized body of literature published on single-fraction HDR brachytherapy shows this modality as safe, but its’ efficacy varies amongst different disease sites. Breast and liver have the most promising data, while prostate has the least encouraging, and conclusions are limited with respect to other cancers. Additional prospective evaluation of single-fraction HDR-BT studies is warranted.

Disclosure

Dr. Mitchell Kamrava, MD, MHDS have conflicts of interest. ABS board of directors’ member at large, ADROP board of directors’ member at large, advisory board fees Theragenics Corp., DSMB GammaTile, Alessa, and Book Royalties Springer.

The other authors report no conflict of interest.

References

1 

Alayed Y, Loblaw A, McGuffin M et al. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. Radiother Oncol 2021; 154: 29-35.

2 

Armstrong S, Brown S, Stancliffe M et al. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. Radiother Oncol 2021; 159: 67-74.

3 

Barnes JM, Gabani P, Sanders M et al. Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience. J Contemp Brachytherapy 2019; 11: 399-408.

4 

Corkum M, Loblaw A, Hasan Y et al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiother Oncol 2021; 156: 160-165.

5 

Gomez-Iturriaga A, Casquero F, Pijoan JI et al. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial. Radiother Oncol 2018; 126: 278-282.

6 

Hoskin P, Rojas A, Ostler P et al. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 2017; 124: 56-60.

7 

Peters M, van Son MJ, Moerland MA et al. MRI-guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study. Int J Radiat Oncol Biol Phys 2019; 104: 1045-1053.

8 

Prada PJ, Cardenal J, Blanco AG et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results. Radiother Oncol 2016; 119: 411-416.

9 

Prada PJ, Ferri M, Cardenal J et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results. Brachytherapy 2018; 17: 845-851.

10 

Reynaud T, Hathout L, Carignan D et al. PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: a phase 2 randomized pilot study. Brachytherapy 2021; 20: 1090-1098.

11 

Siddiqui ZA, Gustafson GS, Ye H et al. Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low-and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2019; 104: 1038-1044.

12 

Slevin F, Hodgson S, Rodda SL et al. Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer. Clin Transl Radiat Oncol 2020; 23: 20-26.

13 

Soatti CP, Delishaj D, D’Amico R et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses–14 years of single-centre experience. J Contemp Brachytherapy 2020; 12: 533-539.

14 

Tharmalingam H, Tsang Y, Ostler P et al.; National UK HDR Prostate Brachytherapy Database. Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. Radiother Oncol 2020; 143: 95-100.

15 

Tsang YM, Tharmalingam H, Belessiotis-Richards K et al. Ultra-hypofractionated radiotherapy for low-and intermediate risk prostate cancer: high-dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiother Oncol 2021; 158: 184-190.

16 

Willigenburg T, van Son MJ, van de Pol SMG et al. Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. Clin Transl Radiat Oncol 2021; 30: 7-14.

17 

Xu MJ, Chen KS, Chang AJ et al. Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience. Brachytherapy 2019; 18: 470-476.

18 

Boulahssass R, Chand ME, Gal J et al. Quality of life and comprehensive geriatric assessment (CGA) in older adults receiving accelerated partial breast irradiation (APBI) using a single fraction of multi-catheter interstitial high-dose rate brachytherapy (MIB). The SiFEBI phase I/II trial. J Geriatr Oncol 2021; 12: 1085-1091.

19 

Hannoun-Lévi JM, Lam Cham Kee D, Gal J et al. Accelerated partial breast irradiation in the elderly: 5-year results of the single fraction elderly breast irradiation (SiFEBI) phase I/II trial. Brachytherapy 2020; 19: 90-96.

20 

Hannoun-Lévi JM, Montagne L, Sumodhee S et al. APBI versus ultra-APBI in the elderly with low-risk breast cancer: a comparative analysis of oncological outcome and late toxicity. Int J Radiat Oncol Biol Phys 2021; 111: 56-67.

21 

Kinj R, Chand ME, Gal J et al. Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. Radiat Oncol 2019; 14: 234.

22 

Kinj R, Chand ME, Gal J et al. Single fraction of accelerated partial breast irradiation in the elderly: early clinical outcome. Radiat Oncol 2018; 13: 174.

23 

Latorre JA, Galdós P, Buznego LA et al. Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results. J Contemp Brachytherapy 2018; 10: 58-63.

24 

Sacchini V, Beal K, Goldberg J et al. Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer. Br J Surg 2008; 95: 1105-1110.

25 

Collettini F, Lutter A, Schnapauff D et al. Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT). Rofo 2014; 186: 606-612.

26 

Collettini F, Schnapauff D, Poellinger A et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 2012; 22: 1101-1109.

27 

Collettini F, Schreiber N, Schnapauff D et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412.

28 

Denecke T, Stelter L, Schnapauff D et al. CT-guided interstitial brachytherapy of hepatocellular carcinoma before liver transplantation: an equivalent alternative to transarterial chemoembolization? Eur Radiol 2015; 25: 2608-2616.

29 

Drewes R, Omari J, Manig M et al. Treatment of hepatic pancreatic ductal adenocarcinoma metastases with high-dose-rate image-guided interstitial brachytherapy: a single center experience. J Contemp Brachytherapy 2019; 11: 329-336.

30 

Jonczyk M, Collettini F, Schnapauff D et al. Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (<4 cm) and large (>4 cm) tumors. Anticancer Res 2018; 38: 5843-5852.

31 

Kieszko D, Cisek P, Kordzińska-Cisek I, Grzybowska-Szatkowska L. Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy. Oncol Lett 2018; 15: 8717-8722.

32 

Ricke J, Mohnike K, Pech M et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485.

33 

Ricke J, Wust P, Stohlmann A et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496-1505.

34 

Ricke J, Wust P, Wieners G et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 2004; 15: 1279-1286.

35 

Schippers AC, Collettini F, Steffen IG et al. Initial experience with CT-guided high-dose-rate brachytherapy in the multimodality treatment of neuroendocrine tumor liver metastases. J Vasc Interv Radiol 2017; 28: 672-682.

36 

Schnapauff D, Collettini F, Hartwig K et al. CT-guided brachytherapy as salvage therapy for intrahepatic recurrence of HCC after surgical resection. Anticancer Res 2015; 35: 319-323.

37 

Schnapauff D, Denecke T, Grieser C et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2012; 35: 581-587. Erratum in: Cardiovasc Intervent Radiol 2011; 34: 1338.

38 

Tselis N, Chatzikonstantinou G, Kolotas C et al. Computed tomography-guided interstitial high dose rate brachytherapy for centrally located liver tumours: a single institution study. Eur Radiol 2013; 23: 2264-2270.

39 

Walter F, Nierer L, Rottler M et al. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiat Oncol 2021; 16: 86.

40 

Wieners G, Mohnike K, Peters N et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy–a phase II-study. Radiother Oncol 2011; 100: 314-319.

41 

Wieners G, Pech M, Hildebrandt B et al. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal “liver-only” metastases: hepatic interstitial brachytherapy plus regional chemotherapy. Cardiovasc Intervent Radiol 2009; 32: 937-945.

42 

Wieners G, Schippers AC, Collettini F et al. CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Hepatobiliary Pancreat Dis Int 2015; 14: 530-538.

43 

Chan MD, Dupuy DE, Mayo-Smith WW et al. Combined radiofrequency ablation and high-dose rate brachytherapy for early-stage non-small-cell lung cancer. Brachytherapy 2011; 10: 253-259.

44 

Fabrini MG, Perrone F, De Franco L et al. Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. Strahlenther Onkol 2009; 185: 524-529. Erratum in: Strahlenther Onkol 2009; 185: 703.

45 

Nag S, Koc M, Schuller DE et al. Intraoperative single fraction high-dose-rate brachytherapy for head and neck cancers. Brachytherapy 2005; 4: 217-223.

46 

Hoskin PJ, de Canha SM, Bownes P et al. High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Radiother Oncol 2004; 73: 195-198.

47 

Kolotas C, Röddiger S, Strassmann G et al. Palliative interstitial HDR brachytherapy for recurrent rectal cancer. Implantation techniques and results. Strahlenther Onkol 2003; 179: 458-463.

48 

Omari J, Drewes R, Matthias M et al. Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy. Brachytherapy 2019; 18: 63-70.

49 

Omari J, Drewes R, Orthmer M et al. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy. Diagn Interv Radiol 2019; 25: 360-367.

50 

Teckie S, Scala LM, Ho F et al. High-dose-rate intraoperative brachytherapy and radical surgical resection in the management of recurrent head-and-neck cancer. Brachytherapy 2013; 12: 228-234.

51 

Xiang L, Zhang JW, Lin S et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer: a phase 1 clinical trial. Int J Radiat Oncol Biol Phys 2015; 92: 1027-1034.

52 

Yoon SM, Suh R, Abtin F et al. Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. Radiat Oncol 2021; 16: 99.

53 

Zhang Y, Ascaso C, Herreros A et al. Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma? Clin Transl Oncol 2020; 22: 1295-1302.

54 

Bartl AJ, Mahoney M, Hennon MW et al. Systematic review of single-fraction stereotactic body radiation therapy for early stage non-small-cell lung cancer and lung oligometastases: how to stop worrying and love one and done. Cancers (Basel) 2022; 14: 790.

55 

Morton G, McGuffin M, Chung HT et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 2020; 146: 90-96.

56 

Mendez LC, Ravi A, Chung H et al. Pattern of relapse and dose received by the recurrent intraprostatic nodule in low-to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy. Brachytherapy 2018; 17: 291-297.

57 

Meneveau MO, Petroni GR, Varhegyi NE et al. Toxicity and cosmetic outcomes after treatment with a novel form of breast IORT. Brachytherapy 2020; 19: 679-684.

58 

Price AT, Kennedy WR, Henke LE et al. Implementing stereotactic accelerated partial breast irradiation using magnetic resonance guided radiation therapy. Radiother Oncol 2021; 164: 275-281.

59 

Mohnike K, Steffen IG, Seidensticker M et al. Radioablation by image-guided (HDR) brachytherapy and transarterial chemoembolization in hepatocellular carcinoma: a randomized phase II trial. Cardiovasc Intervent Radiol 2019; 42: 239-249.

Copyright: © 2022 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.